Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye
Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye zeebizindia@gmail.com (Zee Business) © Provided by Zee Business Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Swati Khandelwal, Zee Business. Edited Excerpts: Q: The company has posted good numbers but the market expected that your numbers will be even better. What would you li...